Titre :
  • Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
Auteur : Bonnefoi, H ; Diebold-Berger, S ; Therasse, P. ; Hamilton, Andrew ; Van de Vijver, Marc J ; MacGrogan, G ; Shepherd, L ; Amaral, N ; Duval, C ; Drijkoningen, R ; Larsimont, Denis ; Piccart-Gebhart, Martine
Informations sur la publication : Annals of oncology, 14, 3, (page 406-413)
Statut de publication : Publié, 2003-03
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Administration, Oral
Adult
Aged
Anthracyclines -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Cyclin D1 -- biosynthesis
Cyclin D1 -- blood
Cyclophosphamide -- administration & dosage
Epirubicin -- administration & dosage
Female
Fluorouracil -- administration & dosage
Gene Expression Regulation, Neoplastic
Granulocyte Colony-Stimulating Factor -- administration & dosage
Humans
Immunohistochemistry
Infusions, Intravenous
Ki-67 Antigen -- analysis
Ki-67 Antigen -- biosynthesis
Middle Aged
Neoadjuvant Therapy
Predictive Value of Tests
Prognosis
Receptor, erbB-2 -- biosynthesis
Receptor, erbB-2 -- blood
Receptors, Estrogen -- analysis
Receptors, Estrogen -- biosynthesis
Receptors, Progesterone -- analysis
Receptors, Progesterone -- biosynthesis
Survival Analysis
Treatment Outcome
Tumor Markers, Biological -- analysis
Tumor Suppressor Protein p53 -- biosynthesis
Tumor Suppressor Protein p53 -- blood
Note : Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0923-7534 
info:pmid/12598346